Navigation
banner

Stem Cell Summit

2018-01-232018-03-012018-01-12
EARLY BIRD DISCOUNT! Register by Mar 01, 2018 to receive 10% off your registration!
Or Register 3 for the price of 2 with the coupon code rcdvb!


ssclaas=mixsessionprlval=1Array ( [3349] => 1 )
Day 1 - Thursday, April 12, 2018
7:30
Continental Breakfast & Registration
ssclaas=mixsessionprlval=1Array ( [3349] => 1 )
8:15
Opening Remarks by Dr. Satish Medicetty, President, GTCbio
ssclaas=mixsessionprlval=1Array ( [3349] => 1 )
ssclaas=mixsessionprlval=1Array ( [3349] => 1 )
ssclaas=mixsessionprlval=1Array ( [3349] => 1 )
10:00
Morning Networking Break
ssclaas=parallelprlval=1Array ( [3351] => 1 [3349] => 1 )
Stem Cell Product Development & Commercialization
Stem Cells for Drug Discovery & Disease Modeling

10:30
 
James Hickman
James Hickman
Chief Scientist
Hesperos
About Speaker: ... Read Full Bio 
 
 
James Hickman
James Hickman
Chief Scientist
Hesperos
 
About Speaker:
Stem Cell Research & Regenerative Medicine
Advances in Adult Stem Cell Research

10:30
 
Hans Keirstead
Hans Keirstead
Chief Executive Officer
AIVITA Biomedical
About Speaker: Dr. Keirstead is an internationally known stem cell expert and has led therapy development for late stage cancers, immune disorders, motor neuron diseases, spinal cord injury and retinal diseases. He is the CEO of AIVITA Biomedical, an Irvine, CA-bas... Read Full Bio 
 
 
Hans Keirstead
Hans Keirstead
Chief Executive Officer
AIVITA Biomedical
 
About Speaker:

Dr. Keirstead is an internationally known stem cell expert and has led therapy development for late stage cancers, immune disorders, motor neuron diseases, spinal cord injury and retinal diseases. He is the CEO of AIVITA Biomedical, an Irvine, CA-based company focused on the advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines. As Full Professor of Anatomy and Neurobiology at the University of California at Irvine he founded and directed the Sue and Bill Gross Stem Cell Research Center. He has been a long-time advisor to several governments on biomedical policy, and was a founding advisor of the California Stem Cell Initiative that resulted in a $3 billion stem cell fund (CIRM).

ssclaas=parallelprlval=1Array ( [3351] => 1 [3349] => 1 )
10:55
 
Glyn Stacey
Glyn Stacey
Head of Division
National Institute for Biological Standards and Control
About Speaker: ... Read Full Bio 
 
 
Glyn Stacey
Glyn Stacey
Head of Division
National Institute for Biological Standards and Control
 
About Speaker:
10:55
 
Sally Temple
Sally Temple
Scientific Director
Neural Stem Cell Institute
About Speaker: ... Read Full Bio 
 
 
Sally Temple
Sally Temple
Scientific Director
Neural Stem Cell Institute
 
About Speaker:
ssclaas=parallelprlval=1Array ( [3351] => 1 [3349] => 1 )
11:20
 
 
TBA (To Be Announced)
TBA (To Be Announced)

 
About Speaker:
11:20
 
Douglas Losordo
Douglas Losordo
Chief Medical Officer, Senior Vice President of Clinical, Medical & Regulatory Affairs
Caladrius Biosciences
About Speaker: Dr. Losordo is the Chief Medical Officer and Senior Vice President of Clinical, Medical and Regulatory Affairs of Caladrius Biosciences, Inc, Clinical Professor of Medicine at  the New York University Langone Medical Center  and Adjunct Professor o... Read Full Bio 
 
 
Douglas Losordo
Douglas Losordo
Chief Medical Officer, Senior Vice President of Clinical, Medical & Regulatory Affairs
Caladrius Biosciences
 
About Speaker:

Dr. Losordo is the Chief Medical Officer and Senior Vice President of Clinical, Medical and Regulatory Affairs of Caladrius Biosciences, Inc, Clinical Professor of Medicine at  the New York University Langone Medical Center  and Adjunct Professor of Medicine at the Northwestern University Feinberg School of Medicine in Chicago, Illinois.

Dr. Losordo’s career has been dedicated to patient care and to the development of novel therapeutics aimed at the reversal or repair of chronic conditions such as heart failure, critical limb ischemia, cancer and diabetes.

A native of Brooklyn, NY, he received his medical degree from the University of Vermont. Dr. Losordo completed an internship, residency and fellowship at St. Elizabeth’s Medical, Boston, Massachusetts, where he subsequently joined the faculty, working with the late Jeff Isner to develop a program in gene therapy and cell-based tissue repair. Dr. Losordo’s group has executed the full “translational medicine” paradigm: identifying potential therapeutic approaches in the laboratory, investigating these strategies in pre-clinical/IND-enabling models and designing and executing first-in-human and proof-of-concept clinical trials as the study sponsor/IND-holder. His work has included developing VEGF gene therapy for myocardial ischemia and diabetic neuropathy, CD34+ cell therapy for refractory angina, critical limb ischemia, severe claudication and coronary microvascular dysfunction and regulatory T cell therapy for autoimmune disease. Two of these candidates advanced to phase 3. At Caladrius Dr. Losordo has initiated a phase 2 study of autologous regulatory T cell therapy for new onset type 1 diabetes in children and recently received Japanese PMDA agreement on a study of CD34 cell therapy for critical limb ischemia targeting conditional approval under the new Japanese regulatory rules governing regenerative therapies. In addition to his own work Dr. Losordo has also mentored numerous scientists and physician-scientists from around the world who now have their own independent programs in translational research.

ssclaas=parallelprlval=1Array ( [3351] => 1 [3349] => 1 )
11:45
 
 
TBA (To Be Announced)
TBA (To Be Announced)

 
About Speaker:
11:45
 
Buddhadeb Dawn
Buddhadeb Dawn
Director
Midwest Stem Cell Therapy Center
About Speaker: ... Read Full Bio 
 
 
Buddhadeb Dawn
Buddhadeb Dawn
Director
Midwest Stem Cell Therapy Center
 
About Speaker:
ssclaas=mixsessionprlval=1Array ( [3349] => 1 )
12:10
Lunch on Your Own
ssclaas=parallelprlval=1Array ( [3351] => 1 [3349] => 1 )
Stem Cell Product Development & Commercialization
Partnering between Industry, Academia, and CROs to Advance Research

1:45
 
Brock Reeve
Brock Reeve
Executive Director
Harvard Stem Cell Institute
About Speaker: ... Read Full Bio 
 
 
Brock Reeve
Brock Reeve
Executive Director
Harvard Stem Cell Institute
 
About Speaker:
Stem Cell Research & Regenerative Medicine
Advances in Pluripotent Stem Cell Research

1:45
 
Mahendra  Rao
Mahendra Rao
Vice President for Regenerative Medicine
New York Stem Cell Foundation
About Speaker: Mahendra Rao  received his MD from Bombay University in India and his PhD in Developmental Neurobiology from the California Institute of Technology. Mahendra Rao is widely known for his research involving human embryonic stem cells (hESCs), iPSC, an... Read Full Bio 
 
 
Mahendra  Rao
Mahendra Rao
Vice President for Regenerative Medicine
New York Stem Cell Foundation
 
About Speaker:

Mahendra Rao  received his MD from Bombay University in India and his PhD in Developmental Neurobiology from the California Institute of Technology. Mahendra Rao is widely known for his research involving human embryonic stem cells (hESCs), iPSC, and other somatic stem cells. Dr. Rao   has an extensive  academic  background  with faculty positions at several  institutions including  the National Insttitutes of Health, Johns Hopkins University School of Medicine, The National Centre for Biological Sciences in Bangalore, India, and the University of Utah School of Medicine.  Dr. Rao has published more than 300 papers on stem cell research and is the co-founder of a neural stem cell company Q therapeutics  and its subsidiary Neuro Q.

Dr. Rao serves on several editorial boards, review panels scientific advisory boards and company boards. He continues to work with the ISCT, ISSCR  and FDA on consent  and other regulatory authorities. Dr Rao is currently the Vice president of Research in Regenerative Medicine at Neuro Q and provides consulting service to several companies focused on regenerative medicine. He currently  serves  on the Board of CESCA, XCell and Stempeutics  and as a consultant  for the New York Stem Cell foundation. He continues to maintain an active research program in neural development and in evaluating cell based screening and therapy to treat disorders of the nervous system.

 

ssclaas=parallelprlval=1Array ( [3351] => 1 [3349] => 1 )
2:10
 
Anthony Ting
Anthony Ting
Vice President
Athersys
About Speaker: Dr. Ting is the Vice President of Regenerative Medicine and Head of Cardiopulmonary Programs. With more than thirty years of experience in cell and stem cell biology, Dr. Ting has developed expertise in translational clinical studies with adult stem ... Read Full Bio 
 
 
Anthony Ting
Anthony Ting
Vice President
Athersys
 
About Speaker:

Dr. Ting is the Vice President of Regenerative Medicine and Head of Cardiopulmonary Programs. With more than thirty years of experience in cell and stem cell biology, Dr. Ting has developed expertise in translational clinical studies with adult stem cell therapies and has been responsible for all stages of the development of MultiStem® from the bench to the bedside. Dr. Ting manages all programs in the cardiovascular and pulmonary areas at the Company, as well as the evaluation of potential new uses for the cell therapy product. Dr. Ting serves on several regenerative medicine society committees including the International Society for Cell Therapy, the Alliance for Regenerative Medicine and the American Society for Gene and Cell Therapy. From 1995 to 2001, Dr. Ting was a Principal Investigator and Head of the Screening for Novel Inhibitors group at the Institute of Molecular and Cell Biology (IMCB) at the National University of Singapore. Prior to joining IMCB, he was a post-doctoral fellow in the department of Molecular and Cellular Physiology at Stanford University. Dr. Ting received his Ph.D. in Cell Biology from Johns Hopkins University and his B.A. in Biology from Amherst College.

2:10
 
 
TBA (To Be Announced)
TBA (To Be Announced)

 
About Speaker:
ssclaas=parallelprlval=2Array ( [3351] => 3 [3349] => 1 )
Array ( [8767] => Array ( [sheduleid] => 8767 [new_session] => 0 [single_conf] => 0 [cfid] => 3349 [schedule_type] => speakerslot [prev] => 1523542200 [next] => 1523545200 )[8773] => Array ( [sheduleid] => 8773 [new_session] => 1 [single_conf] => 0 [cfid] => 3351 [schedule_type] => speakerslot [prev] => 1523542200 [next] => 1523545200 )[8775] => Array ( [sheduleid] => 8775 [new_session] => 0 [single_conf] => 0 [cfid] => 3351 [schedule_type] => speakerslot [prev] => 1523542200 [next] => 1523545200 )[8776] => Array ( [sheduleid] => 8776 [new_session] => 0 [single_conf] => 0 [cfid] => 3351 [schedule_type] => speakerslot [prev] => 1523542200 [next] => 1523545200 ))
2:35
Panel Discussion
Alain Vertès
Alain Vertès
Managing Director
NxR Biotechnologies GmbH
 
Alain Vertès
Alain Vertès
Managing Director
NxR Biotechnologies GmbH
 
About Speaker:

Dr Alain Vertès is a Sloan Fellow from London Business School and a microbiologist by training (University of Illinois at Urbana-Champaign, Institut Pasteur Paris, University of Lille Flandres-Artois). He is a strategy and business development consultant and works to enable funding and partnering in biotechnology. Focusing on technology deployment and innovation commercialization, he has contributed to both white (industrial) and red (pharmaceutical) biotechnology, in different functions including research, manufacturing, contract research, and strategic alliances in pharmaceuticals (Lilly, Pfizer, Roche), biotechnology (Mesoblast), petrochemicals (Mitsubishi Chemical Corporation), public research, and consulting (Australian Strategic Policy Institute, NxR Biotechnologies GmbH). Particularly, he has long been associated with the Research Institute of Innovative Technology for the Earth in Kyoto, Japan, working on developing transformational biorefinery technologies and on deploying green technologies to the marketplace. In the pharmaceutical industry, he champions radical innovation for bringing to patients disease-modifying, paradigm-changing therapeutics such as siRNA, cell- or gene-based pharmaceuticals.

 
TBA (To Be Announced)
TBA (To Be Announced)

 
About Speaker:
 
TBA (To Be Announced)
TBA (To Be Announced)

 
About Speaker:
Array ( [8767] => Array ( [sheduleid] => 8767 [new_session] => 0 [single_conf] => 0 [cfid] => 3349 [schedule_type] => speakerslot [prev] => 1523542200 [next] => 1523545200 )[8773] => Array ( [sheduleid] => 8773 [new_session] => 1 [single_conf] => 0 [cfid] => 3351 [schedule_type] => speakerslot [prev] => 1523542200 [next] => 1523545200 )[8775] => Array ( [sheduleid] => 8775 [new_session] => 0 [single_conf] => 0 [cfid] => 3351 [schedule_type] => speakerslot [prev] => 1523542200 [next] => 1523545200 )[8776] => Array ( [sheduleid] => 8776 [new_session] => 0 [single_conf] => 0 [cfid] => 3351 [schedule_type] => speakerslot [prev] => 1523542200 [next] => 1523545200 ))
2:35
 
 
TBA (To Be Announced)
TBA (To Be Announced)

 
About Speaker:
3:00
 
 
TBA (To Be Announced)
TBA (To Be Announced)

 
About Speaker:
ssclaas=mixsessionprlval=1Array ( [3349] => 1 )
3:25
Afternoon Networking Break
ssclaas=mixsessionprlval=1Array ( [3349] => 1 )
Round Table Sessions
ssclaas=mixsessionprlval=1Array ( [3349] => 1 )
5:15
Networking Reception & Poster Session
ssclaas=mixsessionprlval=1Array ( [3349] => 1 )
7:00
Thank You Dinner (Invitation Only)
ssclaas=mixsessionprlval=1Array ( [3349] => 1 )
Day - 2 Friday, April 13, 2018
 
7:15
Breakfast with Mentors from Academia & Industry (RSVP Only)
ssclaas=mixsessionprlval=1Array ( [3349] => 1 )
7:30
Continental Breakfast for All Attendees
ssclaas=parallelprlval=1Array ( [3351] => 1 [3349] => 1 )
Stem Cell Product Development & Commercialization
Manufacturing and Scalable Processes for Cell Therapy

8:30
 
Katy Spink
Katy Spink
Managing Partner
Dark Horse Consulting
About Speaker: ... Read Full Bio 
 
 
Katy Spink
Katy Spink
Managing Partner
Dark Horse Consulting
 
About Speaker:
Stem Cell Research & Regenerative Medicine
Translation to the Clinic: What’s in the Pipeline

8:30
 
Jacques  Galipeau
Jacques Galipeau
Don and Marilyn Anderson Professor in Oncology; Assistant Dean for Therapeutics Discovery and Development; Director, Program for Advanced Cell Therapy
University of Wisconsin in Madison
About Speaker: ... Read Full Bio 
 
 
Jacques  Galipeau
Jacques Galipeau
Don and Marilyn Anderson Professor in Oncology; Assistant Dean for Therapeutics Discovery and Development; Director, Program for Advanced Cell Therapy
University of Wisconsin in Madison
 
About Speaker:
ssclaas=parallelprlval=1Array ( [3351] => 1 [3349] => 1 )
8:55
 
Emily Titus
Emily Titus
Director, Technology Development
Centre for Commercialization of Regenerative Medicine (CCRM)
About Speaker: ... Read Full Bio 
 
 
Emily Titus
Emily Titus
Director, Technology Development
Centre for Commercialization of Regenerative Medicine (CCRM)
 
About Speaker:
8:55
 
Deborah  Ascheim
Deborah Ascheim
Chief Medical Officer
Capricor
About Speaker: ... Read Full Bio 
 
 
Deborah  Ascheim
Deborah Ascheim
Chief Medical Officer
Capricor
 
About Speaker:
ssclaas=parallelprlval=1Array ( [3351] => 1 [3349] => 1 )
9:20
 
Kevin Murray
Kevin Murray
Vice President, Global Sales
BioSpherix Medical
About Speaker: Sales Manager for BioSpherix, Ltd. BS BioChemistry, MBA Finance & Marketing, 20+ Years experience in the Pharmaceutical/Biotech/Medical Research Industry.... Read Full Bio 
 
 
Kevin Murray
Kevin Murray
Vice President, Global Sales
BioSpherix Medical
 
About Speaker:

Sales Manager for BioSpherix, Ltd. BS BioChemistry, MBA Finance & Marketing, 20+ Years experience in the Pharmaceutical/Biotech/Medical Research Industry.

9:20
 
Charles  Cox
Charles Cox
Director, Children’s Program in Regenerative Medicine
University of Texas Houston
About Speaker: ... Read Full Bio 
 
 
Charles  Cox
Charles Cox
Director, Children’s Program in Regenerative Medicine
University of Texas Houston
 
About Speaker:
ssclaas=parallelprlval=1Array ( [3351] => 1 [3349] => 1 )
9:45
 
 
TBA (To Be Announced)
TBA (To Be Announced)

 
About Speaker:
9:45
 
Bob Valamehr
Bob Valamehr
Vice President, Cancer Immunotherapy & Reprogramming Biology
Fate Therapeutics Inc.
About Speaker: ... Read Full Bio 
 
 
Bob Valamehr
Bob Valamehr
Vice President, Cancer Immunotherapy & Reprogramming Biology
Fate Therapeutics Inc.
 
About Speaker:
ssclaas=mixsessionprlval=1Array ( [3349] => 1 )
10:10
Morning Networking Break
ssclaas=parallelprlval=1Array ( [3351] => 1 [3349] => 1 )
Stem Cell Product Development & Commercialization
Funding & Commercialization of Cell Therapy Moderator

10:40
 
Gil Sambrano
Gil Sambrano
Vice President of Portfolio Development and Review
California Institute for Regenerative Medicine
About Speaker: Gil leads the team responsible for selecting the highest quality stem cell-based projects for CIRM funding from Discovery to Clinical programs.  His team builds and cultivates a world class team of expert reviewers and directs a rigorous review proc... Read Full Bio 
 
 
Gil Sambrano
Gil Sambrano
Vice President of Portfolio Development and Review
California Institute for Regenerative Medicine
 
About Speaker:

Gil leads the team responsible for selecting the highest quality stem cell-based projects for CIRM funding from Discovery to Clinical programs.  His team builds and cultivates a world class team of expert reviewers and directs a rigorous review process through the governing board-appointed Grants Working Group (GWG).

Gil joined CIRM in 2005 as the first Scientific Officer. During his tenure, Gil has contributed to building the vision of CIRM by leading and advancing the scientific review process, constructing grants administration policies, guiding early development of the Grants Management System, and managing the training grant programs. He has been a key point of contact to help applicants and grantees identify appropriate partnering opportunities and navigate the CIRM solicitation and application process.  He leads the conduct of GWG review meetings and has been the primary liaison with patient advocate and scientific members of the GWG.

Prior to CIRM, he was an assistant professor in the department of Cellular and Molecular Pharmacology at UCSF. In 2001, Gil took on a notable position to coordinate efforts of the Alliance for Cellular Signaling, a multi-institutional and multi-disciplinary consortium of scientists led by the Nobel laureate, Alfred G. Gilman, whose goal is to understand the basic principles that regulate signal transduction in cells.

His scientific education includes a B.S. in biology from the University of Texas at El Paso and a Ph.D. in biomedical sciences from the University of California, San Diego. Gil trained as a postdoctoral fellow at the Cardiovascular Research Institute at the University of California San Francisco.

Stem Cell Research & Regenerative Medicine
Revolution in Immunotherapy

10:40
 
Khalid Shah
Khalid Shah
Director Center for Stem Cell Therapeutics and Imaging
Harvard Medical School
About Speaker: Dr. Shah is an Associate Professor at Harvard Medical School. He is also the Director of Center for Stem Cell Therapeutics and Imaging and Vice Chair of Research at Brigham and Women’s Hospital and a Principal Faculty at Harvard Stem Cell Institute... Read Full Bio 
 
 
Khalid Shah
Khalid Shah
Director Center for Stem Cell Therapeutics and Imaging
Harvard Medical School
 
About Speaker:

Dr. Shah is an Associate Professor at Harvard Medical School. He is also the Director of Center for Stem Cell Therapeutics and Imaging and Vice Chair of Research at Brigham and Women’s Hospital and a Principal Faculty at Harvard Stem Cell Institute in Boston. His laboratory focuses on developing therapeutic stem cells for receptor targeted therapies for cancer and testing their efficacy in clinically relevant mouse tumor models. In recent years, Dr. Shah and his team have pioneered major developments in the stem cell therapy field, successfully developing experimental models to understand basic cancer biology and therapeutic stem cells for cancer, particularly brain tumors. These studies have been published in a number of very high impact journals like Nature Neuroscience, PNAS, Nature Reviews Cancer, JNCI, Stem Cells and Lancet Oncology, validating the use of therapeutic stem cells alone and in combination with clinically approved drugs for cancer therapy.

Recently, Dr. Shah's work has caught the attention in the public domain and as such it has been highlighted in the media world-wide including features on BBC and CNN. Dr. Shah holds current positions on numerous councils, advisory and editorial boards in the fields of stem cell therapy and oncology. The technologies from Dr. Shah’s laboratory have led to the foundation of a biotech company, AMASA Technologies Inc. whose main objective is the clinical translation of therapeutic stem cells in cancer patients.

ssclaas=parallelprlval=1Array ( [3351] => 1 [3349] => 1 )
11:05
 
Patrick Keenan
Patrick Keenan
Managing Director
Prevail Partners
About Speaker: ... Read Full Bio 
 
 
Patrick Keenan
Patrick Keenan
Managing Director
Prevail Partners
 
About Speaker:
11:05
 
Marcela Maus
Marcela Maus
Assistant Professor of Medicine; Director of Cellular Immunotherapy
Harvard Medical School; Cancer Center, Massachusetts General Hospital
About Speaker: ... Read Full Bio 
 
 
Marcela Maus
Marcela Maus
Assistant Professor of Medicine; Director of Cellular Immunotherapy
Harvard Medical School; Cancer Center, Massachusetts General Hospital
 
About Speaker:
ssclaas=parallelprlval=2Array ( [3351] => 3 [3349] => 1 )
Array ( [8795] => Array ( [sheduleid] => 8795 [new_session] => 1 [single_conf] => 0 [cfid] => 3351 [schedule_type] => speakerslot [prev] => 1523617500 [next] => 1523620500 )[8796] => Array ( [sheduleid] => 8796 [new_session] => 0 [single_conf] => 0 [cfid] => 3351 [schedule_type] => speakerslot [prev] => 1523617500 [next] => 1523620500 )[8797] => Array ( [sheduleid] => 8797 [new_session] => 0 [single_conf] => 0 [cfid] => 3351 [schedule_type] => speakerslot [prev] => 1523617500 [next] => 1523620500 )[8814] => Array ( [sheduleid] => 8814 [new_session] => 0 [single_conf] => 0 [cfid] => 3349 [schedule_type] => speakerslot [prev] => 1523617500 [next] => 1523620500 ))
11:30
Panel Discussion
Gail  Naughton
Gail Naughton
Chief Executive Officer
Histogen
 
Gail  Naughton
Gail Naughton
Chief Executive Officer
Histogen
 
About Speaker:
Michael May
Michael May
President & CEO
Centre for Commercialization of Regenerative Medicine (CCRM)
 
Michael May
Michael May
President & CEO
Centre for Commercialization of Regenerative Medicine (CCRM)
 
About Speaker:
 
TBA (To Be Announced)
TBA (To Be Announced)

 
About Speaker:
Array ( [8795] => Array ( [sheduleid] => 8795 [new_session] => 1 [single_conf] => 0 [cfid] => 3351 [schedule_type] => speakerslot [prev] => 1523617500 [next] => 1523620500 )[8796] => Array ( [sheduleid] => 8796 [new_session] => 0 [single_conf] => 0 [cfid] => 3351 [schedule_type] => speakerslot [prev] => 1523617500 [next] => 1523620500 )[8797] => Array ( [sheduleid] => 8797 [new_session] => 0 [single_conf] => 0 [cfid] => 3351 [schedule_type] => speakerslot [prev] => 1523617500 [next] => 1523620500 )[8814] => Array ( [sheduleid] => 8814 [new_session] => 0 [single_conf] => 0 [cfid] => 3349 [schedule_type] => speakerslot [prev] => 1523617500 [next] => 1523620500 ))
11:30
 
 
TBA (To Be Announced)
TBA (To Be Announced)

 
About Speaker:
11:55
 
 
TBA (To Be Announced)
TBA (To Be Announced)

 
About Speaker:
ssclaas=parallelprlval=0Array ( [3349] => 2 )
Lunch Session: Regulatory Challenges in Cell Therapy

Array ( [8798] => Array ( [sheduleid] => 8798 [new_session] => 1 [single_conf] => 0 [cfid] => 3349 [schedule_type] => speakerslot [prev] => 1523620500 [next] => 1523625600 )[8801] => Array ( [sheduleid] => 8801 [new_session] => 0 [single_conf] => 0 [cfid] => 3349 [schedule_type] => speakerslot [prev] => 1523620500 [next] => 1523625600 ))
ssclaas=mixsessionprlval=1Array ( [3349] => 1 )
ssclaas=mixsessionprlval=1Array ( [3349] => 1 )
1
ssclaas=parallelprlval=0Array ( [3349] => 4 )
Keynote Panel Discussion
Erin Kimbrel
Array ( [8806] => Array ( [sheduleid] => 8806 [new_session] => 1 [single_conf] => 0 [cfid] => 3349 [schedule_type] => speakerslot [prev] => 1523627400 [next] => 1523631000 )[8808] => Array ( [sheduleid] => 8808 [new_session] => 0 [single_conf] => 0 [cfid] => 3349 [schedule_type] => speakerslot [prev] => 1523627400 [next] => 1523631000 )[8809] => Array ( [sheduleid] => 8809 [new_session] => 0 [single_conf] => 0 [cfid] => 3349 [schedule_type] => speakerslot [prev] => 1523627400 [next] => 1523631000 )[8810] => Array ( [sheduleid] => 8810 [new_session] => 0 [single_conf] => 0 [cfid] => 3349 [schedule_type] => speakerslot [prev] => 1523627400 [next] => 1523631000 ))
ssclaas=mixsessionprlval=1Array ( [3349] => 1 )
Summit Concludes